Show simple item record

dc.contributor.authorBanister, S.
dc.contributor.authorAdams, A.
dc.contributor.authorKevin, R.
dc.contributor.authorMacdonald, C.
dc.contributor.authorGlass, M.
dc.contributor.authorBoyd, R.
dc.contributor.authorConnor, M.
dc.contributor.authorMcGregor, I.
dc.contributor.authorHavel, C.
dc.contributor.authorBright, S.
dc.contributor.authorVilamala, M.
dc.contributor.authorLladanosa, C.
dc.contributor.authorBarratt, Monica
dc.contributor.authorGerona, R.
dc.date.accessioned2018-12-13T09:10:03Z
dc.date.available2018-12-13T09:10:03Z
dc.date.created2018-12-12T02:46:25Z
dc.date.issued2018
dc.identifier.citationBanister, S. and Adams, A. and Kevin, R. and Macdonald, C. and Glass, M. and Boyd, R. and Connor, M. et al. 2018. Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold- hopping analog of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA. Drug Testing and Analysis.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/71444
dc.identifier.doi10.1002/dta.2491
dc.description.abstract

© 2018 John Wiley & Sons, Ltd. Synthetic cannabinoid receptor agonists (SCRAs) are a dynamic class of new psychoactive substances (NPS), with novel chemotypes emerging each year. Following the putative detection of 5F-CUMYL-P7AICA in Australia in 2016, the scaffold-hopping SCRAs 5F-CUMYL-PICA, 5F-CUMYL-PINACA, and 5F-CUMYL-P7AICA were synthesized and characterized by nuclear magnetic resonance (NMR) spectroscopy, gas chromatography–mass spectrometry (GC–MS), and liquid chromatography–quadrupole time-of-flight–MS (LC–QTOF–MS). Since little is known of the pharmacology of 7-azaindole SCRAs like 5F-CUMYL-P7AICA, the binding affinities and functional activities of all compounds at cannabinoid type 1 and type 2 receptors (CB1 and CB2, respectively) were assessed using tritiated radioligand competition experiments and fluorescence-based plate reader membrane potential assays. Despite CB1 binding affinities differing by over two orders of magnitude (Ki = 2.95–174 nM), all compounds were potent and efficacious CB1 agonists (EC50 = 0.43–4.7 nM), with consistent rank order for binding and functional activity (5F-CUMYL-PINACA >5F-CUMYL-PICA >5F-CUMYL-P7AICA). Additionally, 5F-CUMYL-P7AICA was found to exert potent cannabimimetic effects in mice, inducing hypothermia (6°C, 3 mg/kg) through a CB1-dependent mechanism.

dc.publisherJohn Wiley & Sons, Ltd.
dc.titleSynthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold- hopping analog of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA
dc.typeJournal Article
dcterms.source.issn1942-7603
dcterms.source.titleDrug Testing and Analysis
curtin.departmentNational Drug Research Institute (NDRI)
curtin.accessStatusFulltext not available


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record